<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089658</url>
  </required_header>
  <id_info>
    <org_study_id>MS100070_0308</org_study_id>
    <nct_id>NCT03089658</nct_id>
  </id_info>
  <brief_title>Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)</brief_title>
  <official_title>Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      Expanded access to Avelumab solution for infusion will be made available for adult patients
      with mMCC whose disease has progressed after receiving at least one prior chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Metastatic Merkel Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable metastatic Merkel cell carcinoma according to Response Evaluation Criteria
             In Solid Tumors version 1.1 (RECIST v1.1), has failed at least one line of adequately
             dosed chemotherapy in the metastatic setting and has subsequently progressed (where
             adequate dosing is defined as a minimum of 2 cycles)

          -  Not eligible for participation in any ongoing clinical trial for Merkel cell carcinoma
             including the Javelin Merkel 200 study (NCT02155647)

          -  Adequate hematological, hepatic and renal function as defined in the protocol

        Exclusion Criteria:

          -  Brain metastases

          -  Prior organ transplantation, including allogeneic stem cell transplantation

          -  History of testing positive for human immunodeficiency virus (HIV) or known AIDS or
             active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Concurrent, active, malignant disease (other than Merkel cell carcinoma) with the
             exception of basal or squamous cell carcinoma of the skin or carcinoma in situ as
             defined in protocol

          -  Previous or active autoimmune disease requiring systemic immunosuppressive therapy

          -  Known severe hypersensitivity reactions to monoclonal antibodies, any history of
             anaphylaxis, or uncontrolled asthma

          -  Clinically significant (that is, active) cardiovascular disease: cerebral vascular
             accident / stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months
             prior to enrollment) unstable angina, congestive heart failure (New York Heart
             Association Classification Class ≥ II), or serious cardiac arrhythmia requiring
             medication

          -  Persisting toxicity related to prior therapy of Grade &gt;1 NCI-CTCAE v 4.03 (alopecia
             and sensory neuropathy Grade ≤ 2 is acceptable)

          -  Being treated with chronic systemic corticosteroids or other chronic therapeutic
             immunosuppression

          -  Pregnant or lactating (for women of childbearing potential)

          -  Not using a highly effective contraception if the risk of conception exists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Avelumab ATU Unit</last_name>
    <phone>+33 1 44 90 39 09</phone>
    <email>atu-avelumab@parexel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Avelumab ATU Unit</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Merkel Cell Carcinoma</keyword>
  <keyword>Expanded Access Program</keyword>
  <keyword>Temporary Authorisation for Use</keyword>
  <keyword>Avelumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

